OncoMatch/Clinical Trials/NCT06114004
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
Is NCT06114004 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Selinexor 20 MG and Gemcitabine for sarcoma,soft tissue.
Treatment: Selinexor 20 MG · Gemcitabine — Phase I-II, non-randomized, single-arm, open-label, multicenter, international clinical trial. Patients with advanced soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) will receive selinexor in combination with gemcitabine.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced disease
Patients have previously received at least one previous line of systemic therapy.
Cannot have received: XPO1 inhibitor (selinexor)
Prior selinexor or another XPO1 inhibitor treatment.
Cannot have received: gemcitabine-containing treatment (gemcitabine)
Administration of a previous gemcitabine-containing treatment.
Cannot have received: systemic therapy
Three or more systemic treatment lines (including both chemotherapy and targeted therapy) for advanced disease (localized unresectable or metastatic).
Cannot have received: anti-cancer therapy or investigational product
Patients who have received any other anti-cancer therapy or investigational product in the last 21 days prior to enrollment.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/mm³; Platelet count ≥ 100,000/mm³; Hgb not specified
Kidney function
Creatinine ≤ 1.5 mg/dL
Liver function
Bilirubin ≤ 1.5 mg/dL; AST and ALT ≤ 2.5 times upper limit of normal
Cardiac function
Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan
Adequate hepatic, renal, cardiac, and hematologic function. Laboratory tests as follows: Absolute neutrophil count ≥ 1,500/mm³; Platelet count ≥ 100,000/mm³; Bilirubin ≤ 1.5 mg/dL; AST and ALT ≤ 2.5 times upper limit of normal; Creatinine ≤ 1.5 mg/dL. Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify